The data contain body weights, plasma free fatty acids concentrations and cardiac uncoupling protein-3 protein levels for wild-type and mdx mice. The data provide heart rates, left ventricular contractile functions, coronary flow, phosphocreatine concentrations, and adenosine 5'-triphosphate (ATP) concentrations throughout hypoxia in mdx mouse hearts. This data article also provides left ventricular contractile functions after low flow ischemia with and without glucose, glycogen levels before ischemia or hypoxia, glucose uptake rates during low flow ischemia and insulin stimulation, and insulin-stimulated phospho-Akt protein levels, a protein in insulin signaling, in mdx mouse hearts.
a b s t r a c t
The data contain body weights, plasma free fatty acids concentrations and cardiac uncoupling protein-3 protein levels for wild-type and mdx mice. The data provide heart rates, left ventricular contractile functions, coronary flow, phosphocreatine concentrations, and adenosine 5'-triphosphate (ATP) concentrations throughout hypoxia in mdx mouse hearts. This data article also provides left ventricular contractile functions after low flow ischemia with and without glucose, glycogen levels before ischemia or hypoxia, glucose uptake rates during low flow ischemia and insulin stimulation, and insulin-stimulated phospho-Akt protein levels, a protein in insulin signaling, in mdx mouse hearts.
& All data are available with this article.
Value of the data
This data can be used to further investigate the role of dystrophin in obesity and elevated serum free fatty acids levels in human Duchenne muscular dystrophy patients.
The data can be used to determine whether decreased phosphocreatine and ATP concentrations cause decreased contractile functions after hypoxia or vice verse in mdx mouse hearts.
Glucose uptake rates and phospho-Akt data can be used to investigate the role of dystrophin in signaling.
Data
Mdx mice have abnormal body weights, plasma free fatty acids concentrations and cardiac uncoupling protein-3 protein levels compared with wild-type mice. Mdx mouse hearts have decreased left ventricular contractile functions and faster ATP loss rates during hypoxia compared with wild-types. Mdx mouse hearts also have higher left ventricular end-diastolic pressures and lower glucose uptake rates during low flow ischemia than wild-types. Insulin-stimulated phosphoAkt protein levels are similar in all mouse hearts while mdx mouse hearts have lower glucose uptake rates in response to insulin than wild-types.
Experimental design, materials, and methods
Experiments were carried out using male wild-type (C57BL10) (n ¼ 61) and age-matched mdx (n ¼ 62) mice at 8 months. All the procedures were approved by the Animal Ethics Review Committees, University of Oxford, and by the Home Office, United Kingdom. Plasma free fatty acids concentrations were measured using NEFA kit (Wako Chemicals). Western blot quantified protein levels with anti-uncoupling protein-3, anti-phospho-Akt (Cell Signaling) and anti-GAPDH (Abcam). Isolated whole Langendorff-perfused mouse hearts were equilibrated with fatty acids free KrebsHenseleit buffer gassed with 95% O 2 -5% CO 2 (PaO 2 ¼ $ 90 mmHg), and subjected to hypoxia with buffer gassed with 95% N 2 -5% CO 2 (PaO 2 ¼ $ 45 mmHg) and reoxygenation. Left ventricular pressures and coronary flow were recorded. Protocols were shown in Fig. 1 . Glycogen levels before ischemia or hypoxia were determined [1] . Glucose uptake rates were calculated using D- [2- 3 H] glucose during low flow ischemia (0.5 ml min À 1 gww À 1 ) and in response to insulin [2] . Statistical significance was assessed using one-way analysis of variance followed by Student's t-test.
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This work is part of Wen Zhang's DPhil thesis and was supported by the British Heart Foundation (grant reference PG/07/030/22667). Fig. 1 . Body weights, plasma free fatty acids, western blot, hypoxia, low flow ischemia, and glycogen data. A: Body weights (n ¼ 28 for wild-type, n ¼ 30 for mdx); B: Plasma free fatty acids concentrations (n ¼ 4 for wild-type, n ¼ 5 for mdx); C: Uncoupling protein-3 (UCP3) western blot (n ¼ 5 for wild-type, n ¼ 5 for mdx); D-F, H: Hypoxia with glucose (n ¼ 10 for wildtype; n ¼ 12 for mdx); I-K, M: Hypoxia with pyruvate and lactate (n ¼ 4 for wild-type; n ¼ 5 for mdx); N, O: Phosphocreatine and ATP concentrations throughout hypoxia (n ¼ 4 for wild-type, n ¼ 5 for mdx). Q, R: Low flow ischemia with glucose (n ¼ 10 for wild-type; n ¼ 9 for mdx); S: Glucose uptake rates during low flow ischemia (n ¼ 6 for wild-type; n ¼ 5 for mdx); T, U: Low flow ischemia with pyruvate and lactate (n ¼ 4 for wild-type; n ¼ 5 for mdx); V: Cardiac glycogen levels (n ¼ 6 for wild-type and n ¼ 5 for mdx in both perfusions); W, X: Insulin-stimulated glucose uptake rates and phospho-Akt western blot (n ¼ 5 for wild-type without and with insulin; n ¼ 6 for mdx without and with insulin). LV RPP, left ventricular rate-pressure product; EDP, end-diastolic pressure; MRS, magnetic resonance spectroscopy. Substrate G: 11 mM glucose; GPL: 11 mM glucose, 1.8 mM pyruvate and 0.2 mM lactate; PL: 1.8 mM pyruvate and 0.2 mM lactate. Data are expressed as means 7 SEM. * P o 0.05 vs. wild-type; † P o 0.01 vs. wild-type; ‡ P o 0.001 vs. non-insulin-stimulated wild-type; § P o 0.001 vs. non-insulin-stimulated mdx; ǁ P o 0.05 vs. insulin-stimulated wild-type.
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